We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Stemline Therapeutics Inc | NASDAQ:STML | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.83 | 11.90 | 12.50 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
(Amendment No. 3)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
Stemline Therapeutics, Inc.
(Name of Subject Company)
Stemline Therapeutics, Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
85858C107
(CUSIP Number of Class of Securities)
Ivan Bergstein, M.D.
Chairman, President and Chief Executive Officer
750 Lexington Avenue
Eleventh Floor
New York, New York 10022
(646) 502-2311
(Name, address, and telephone numbers of person authorized to receive notices and communications on
behalf of the persons filing statement)
Copies to:
Graham Robinson
|
|
Matthew Mamak
|
o Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
This Amendment No. 3 (this Amendment) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, this Schedule 14D-9) filed by Stemline Therapeutics, Inc. (Stemline) with the Securities and Exchange Commission (the SEC) on May 12, 2020, relating to the tender offer by Mercury Merger Sub, Inc., a Delaware corporation (Purchaser) and wholly owned subsidiary of Berlin-Chemie AG, a company formed under the laws of Germany (Parent), and an indirect wholly owned subsidiary of A. Menarini - Industrie Farmaceutiche Riunite - S.r.l. (Menarini), a company formed under the laws of Italy, to purchase all of the issued and outstanding shares of common stock, par value $0.0001 per share (the Shares), of Stemline for (i) $11.50 per Share, net to the seller in cash, without interest, plus (ii) one (1) contingent value right per Share as set forth in the Contingent Value Rights Agreement, and subject to any withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, filed by Parent, Purchaser and Menarini with the SEC on May 12, 2020 (as amended or supplemented from time to time), and in the related Letter of Transmittal (as amended or supplemented from time to time).
Except to the extent specifically provided in this Amendment, the information set forth in this Schedule 14D-9 remains unchanged. Capitalized terms used, but not otherwise defined, in this Amendment shall have the meanings ascribed to them in this Schedule 14D-9. This Amendment is being filed to reflect certain updates as set forth below.
ITEM 8. ADDITIONAL INFORMATION
Item 8 of this Schedule 14D-9 is hereby amended and supplemented by deleting the paragraph under the heading Item 8. Additional InformationLegal Proceedings on page 56 of this Schedule 14D-9 and replacing it with the following paragraphs:
On May 13, 2020, a purported stockholder of Stemline filed a lawsuit in the United States District Court for the Southern District of New York against Stemline and its directors, captioned Shiva Stein v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-30716. On May 15, 2020, a purported stockholder of Stemline filed a lawsuit in the United States District Court for the Southern District of New York against Stemline and its directors, captioned Don Johnston v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-03804 (the Johnston Complaint). On May 19, 2020, a purported stockholder of Stemline filed a lawsuit in the United States District Court for the Southern District of New York against Stemline and its directors, captioned Matthew Lee v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-03899. On May 20, 2020, a purported stockholder of Stemline filed a putative class action lawsuit in the United States District Court for the Southern District of New York against Stemline and its directors, captioned Michael Leon v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-03931 (the Leon Complaint). On May 20, 2020, a purported stockholder of Stemline filed a lawsuit in the United States District Court for the Eastern District of New York against Stemline and its directors, captioned Eric Wolfe v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-02280 (the Wolfe Complaint). The complaints allege that the Schedule 14D-9 omits material information or contains misleading disclosures and that, as a result, (i) all of the defendants violated Section 14(e) of the Exchange Act, (ii) all of the defendants violated Section 14(d)(4) of the Exchange Act (except for the Leon Complaint) and (iii) all of Stemlines directors violated Section 20(a) of the Exchange Act. In addition, the Johnston Complaint alleges that each of the directors violated his fiduciary duty of candor and disclosure. The complaints seek, among other things, (i) injunctive relief preventing the consummation of the Transactions, (ii) rescissory damages or rescission in the event that the Transactions have already been consummated (except for the Johnston Complaint), (iii) damages (except for the Wolfe Complaint) and (iv) plaintiffs attorneys and experts fees. The defendants believe the claims asserted in the complaints are without merit.
On May 20, 2020, a purported stockholder of Stemline filed a putative class action lawsuit in the United States District Court for the District of Delaware against Stemline, Stemlines directors, Parent and Purchaser, captioned Adam Franchi v. Stemline Therapeutics, Inc., et al., Case No. 1:20-cv-00683 (the Franchi Complaint). The Franchi Complaint alleges that all of the defendants violated Sections 14(e) and 14(d) of the Exchange Act and Parent and each of Stemlines directors violated Section 20(a) of the Exchange Act. The Franchi Complaint seeks, among other things, (i) injunctive relief preventing the consummation of the Transactions, (ii) rescissory damages or rescission in the event that the Transactions have already been consummated and (iii) plaintiffs attorneys and experts fees. The defendants believe the claims asserted in the Franchi Complaints are without merit.
SIGNATURE
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: May 21, 2020 |
Stemline Therapeutics, Inc. |
|
|
|
|
|
By: |
/s/ Kenneth Hoberman |
|
Name: |
Kenneth Hoberman |
|
Title: |
Chief Operating Officer |
1 Year Stemline Therapeutics Chart |
1 Month Stemline Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions